Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun;19(6):473-482.
doi: 10.1080/14737140.2019.1622417. Epub 2019 May 31.

Targeting the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma

Affiliations
Free PMC article
Review

Targeting the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma

Veethika Pandey et al. Expert Rev Anticancer Ther. .
Free PMC article

Abstract

Introduction: The dismally slow improvement in patient survival over the years for pancreatic cancer patients is mainly due to two factors: the late diagnosis, at which point the disease is spread to distant organs; and the fact that tumor cells are surrounded by a dense, highly immunosuppressive microenvironment. The tumor microenvironment not only shields pancreatic cancer cells from chemotherapy but also leaves it unsusceptible to various immunotherapeutic strategies that have been proven successful in other types of cancer. Areas covered: This review highlights the main components of the pancreatic tumor microenvironment, how they cross-talk with each other to generate stroma and promote tumor growth. Additionally, we discuss the most promising treatment targets in the microenvironment whose modulation can be robustly tested in combination with standard of care chemotherapy. Currently, active clinical trials for pancreatic cancer involving components of the microenvironment are also listed. Expert opinion: Although immunotherapeutic approaches involving checkpoint inhibition are being pursued enthusiastically, there is still more work to be done with several other emerging immune targets that could provide therapeutic benefit.

Keywords: Pancreatic cancer; fibroblasts; myeloid derived suppressor cells; stellate cells; tumor microenvironment; tumor-associated macrophages.

Conflict of interest statement

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Similar articles

See all similar articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback